Loading
Life sciences · Journal article
Microbiology Spectrum · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Candida (Candidozyma) auris ( C. auris ) poses an urgent public health threat due to its widespread emergence, antimicrobial resistance, and ability to cause severe infections and outbreaks associated with high mortality rates. In this study, we phenotypically and genotypically characterized antifungal susceptibility profiles and used whole-genome sequencing (WGS) to assess overall genetic diversity and to identify clonal clusters. From July 2020 to December 2025, a total of 118 C. auris isolates from 97 patients were collected at a tertiary hospital in New York City. Antifungal susceptibility testing and WGS were performed on all clinical isolates to characterize their clade-specific antifungal resistance genes and intra-clade genetic variations. Ninety-nine percentage of the C. auris isolates demonstrated phenotypic fluconazole resistance. Resistance to echinocandins was observed in 7.6% (9/118) of isolates, and resistance to amphotericin B was found in 54% (64/118). WGS confirmed that all 118 isolates belonged to the CDC-defined Clade Ic. Azole resistance mutations in the ERG11 and CDR1 genes were detected in 100% (118/118) of the isolates, and mutations in the TAC1B gene were present in 92.4% (109/118) of the isolates, including one case with a unique set of mutations ( ERG11 -Y132F, CDR1 -E709D, TAC1B -A583S). Mutations in the FKS1 gene were identified in 5.9% (7/118) of isolates though these were not consistently linked to echinocandin resistance. Genomic analysis also revealed that individual patients frequently carried the same strain throughout the study. Furthermore, multiple strains emerged simultaneously across the hospital each year. This suggests that numerous patients were likely already colonized upon admission, rather than acquiring the pathogen through intra-hospital transmission. The presence of multiple C. auris strains with varying resistance patterns poses significant therapeutic challenges. Genomic typing can help hospitals understand the diversity of their C. auris isolates to track their spread, identify potential outbreaks, and ensure the effectiveness of infection control measures. IMPORTANCE Candida (Candidozyma) auris is an emerging, multidrug-resistant fungal pathogen designated by the Centers for Disease Control and Prevention (CDC) as an urgent public threat. Traditionally, C. auris infections have been considered predominantly nosocomial, with outbreaks typically attributed to a single clonal lineage spreading within healthcare facilities. However, the genomic analysis performed in our study identified multiple distinct clusters of genetic variations within a single clade, suggesting that infections were not derived from a single source. This genomic diversity indicates that many patients may have acquired C. auris prior to hospital admission. Nevertheless, intra-hospital transmission was evident, as patient-to-patient spread facilitated the dissemination of various clonal lineages within the healthcare environment. These findings underscore the complex epidemiology of C. auris and highlight the urgent need for stringent infection control measures both within and beyond hospital settings.